These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 23557519)
1. Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. Huber K; Connolly SJ; Kher A; Christory F; Dan GA; Hatala R; Kiss RG; Meier B; Merkely B; Pieske B; Potpara T; Stępińska J; Klun NV; Vinereanu D; Widimský P Int J Clin Pract; 2013 Jun; 67(6):516-26. PubMed ID: 23557519 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Skjøth F; Larsen TB; Rasmussen LH; Lip GY Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485 [TBL] [Abstract][Full Text] [Related]
3. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. Cheng JW; Barillari G J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983 [TBL] [Abstract][Full Text] [Related]
4. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Huisman MV; Lip GY; Diener HC; Brueckmann M; van Ryn J; Clemens A Thromb Haemost; 2012 May; 107(5):838-47. PubMed ID: 22318514 [TBL] [Abstract][Full Text] [Related]
5. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. Lip GY; Larsen TB; Skjøth F; Rasmussen LH J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324 [TBL] [Abstract][Full Text] [Related]
6. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583 [TBL] [Abstract][Full Text] [Related]
7. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. Rasmussen LH; Larsen TB; Graungaard T; Skjøth F; Lip GY BMJ; 2012 Nov; 345():e7097. PubMed ID: 23129490 [TBL] [Abstract][Full Text] [Related]
8. Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation. Deitelzweig S Cardiovasc Ther; 2014 Apr; 32(2):74-81. PubMed ID: 24119252 [TBL] [Abstract][Full Text] [Related]
9. Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges. Mangiafico RA; Mangiafico M Curr Med Chem; 2012; 19(27):4688-98. PubMed ID: 22830344 [TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Schneeweiss S; Gagne JJ; Patrick AR; Choudhry NK; Avorn J Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):480-6. PubMed ID: 22787066 [TBL] [Abstract][Full Text] [Related]
11. Dabigatran etexilate: A novel oral direct thrombin inhibitor. Blommel ML; Blommel AL Am J Health Syst Pharm; 2011 Aug; 68(16):1506-19. PubMed ID: 21817082 [TBL] [Abstract][Full Text] [Related]
12. The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients. Ellis CR; Kaiser DW Vasc Health Risk Manag; 2013; 9():341-52. PubMed ID: 23874100 [TBL] [Abstract][Full Text] [Related]
14. Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review. Alcocer L Am J Cardiovasc Drugs; 2016 Jun; 16(3):171-82. PubMed ID: 26923792 [TBL] [Abstract][Full Text] [Related]
15. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548 [TBL] [Abstract][Full Text] [Related]
16. Novel oral anticoagulants: a review of the literature and considerations in special clinical situations. Akwaa F; Spyropoulos AC Hosp Pract (1995); 2013 Feb; 41(1):8-18. PubMed ID: 23466963 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628 [TBL] [Abstract][Full Text] [Related]
18. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Ezekowitz MD; Connolly S; Parekh A; Reilly PA; Varrone J; Wang S; Oldgren J; Themeles E; Wallentin L; Yusuf S Am Heart J; 2009 May; 157(5):805-10, 810.e1-2. PubMed ID: 19376304 [TBL] [Abstract][Full Text] [Related]
19. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey. Pisters R; Nieuwlaat R; Lane DA; Crijns HJ; Lip GY Thromb Haemost; 2013 Feb; 109(2):328-36. PubMed ID: 23179181 [TBL] [Abstract][Full Text] [Related]
20. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Scaglione F Clin Pharmacokinet; 2013 Feb; 52(2):69-82. PubMed ID: 23292752 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]